Authors
Xuan Xia, Junming Tan, Shuhong Zhang, Tanyuxuan Yang, Xiaojuan Chen, Jianyan Qin, Reza Yousefi, Yongheng Chen
Published in
Biochemical pharmacology. Pages 118662. Nov 17, 2026. Epub Nov 17, 2026.
Abstract
Short therapeutic peptides are often limited by rapid systemic clearance and insufficient in vivo persistence. Although formulation- and carrier-based approaches can improve delivery, intrinsic sequence optimization remains underexplored. Using thymosin α1 (Tα-1) as a clinically validated model, we applied structure-guided intrinsic stabilization to improve apparent systemic persistence while preserving context-dependent immunomodulatory function. An AlphaFold-derived comparative scaffold, FoldX single-site scanning, and DUET cross-validation identified D15 and E27 as stability-permissive engineering sites. D15M showed the most consistent overall improvement, whereas E27R supported E27 as a second optimization site. Both variants retained native-like structural features, resisted serum-associated degradation, and showed prolonged apparent systemic persistence after both subcutaneous and intravenous administration. These gains were accompanied by preserved biological activity in immunosuppressed mice, a tumor xenograft model, murine and human macrophage systems, and donor-derived peripheral blood mononuclear cells. The optimized variants maintained the context-dependent immunomodulatory profile of native Tα-1 rather than producing a broad constitutive increase in intrinsic activity. These findings support structure-guided intrinsic stabilization as a complementary strategy for improving the developability and systemic performance of short therapeutic peptides without compromising biological function.
PMID:
43044988
Bibliographic data and abstract were imported from PubMed on 18 Nov 2026.
Read full publication at:
Please sign in
to see all details.
Advertisement
Stats
- Recommendations n/a n/a positive of 0 vote(s)
- Views 6
- Comments 0